Kyntra Bio annual operating margin
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kyntra Bio's operating margin was −712.66% for fiscal 2025.
View full Kyntra Bio company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −712.66% | −204.85 pp |
| 2024 | 2024-12-31 | −507.80% | +181.73 pp |
| 2023 | 2023-12-31 | −689.53% | −475.63 pp |
| 2022 | 2022-12-31 | −213.90% | −91.28 pp |
| 2021 | 2021-12-31 | −122.62% | −13.79 pp |
| 2020 | 2020-12-31 | −108.83% | −74.02 pp |
| 2019 | 2019-12-31 | −34.81% | +5.90 pp |
| 2018 | 2018-12-31 | −40.71% | +48.82 pp |
| 2017 | 2017-12-31 | −89.53% | −62.21 pp |
| 2016 | 2016-12-31 | −27.32% | +15.61 pp |
| 2015 | 2015-12-31 | −42.93% | −6.52 pp |
| 2014 | 2014-12-31 | −36.41% | −28.63 pp |
| 2013 | 2013-12-31 | −7.78% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −369.66% | +175.06 pp |
| Q4 2025 | 2025-12-31 | −1,058.10% | −830.62 pp |
| Q3 2025 | 2025-09-30 | −502.88% | +38271.10 pp |
| Q2 2025 | 2025-06-30 | −894.07% | +3756.03 pp |
| Q1 2025 | 2025-03-31 | −544.72% | −350.82 pp |
| Q4 2024 | 2024-12-31 | −227.49% | −69.31 pp |
| Q3 2024 | 2024-09-30 | −38,773.98% | −38575.31 pp |
| Q2 2024 | 2024-06-30 | −4,650.10% | −4439.68 pp |
| Q1 2024 | 2024-03-31 | −193.90% | −1.42 pp |
| Q3 2023 | 2023-09-30 | −158.18% | +437.04 pp |
| Q2 2023 | 2023-06-30 | −198.67% | +63.78 pp |
| Q1 2023 | 2023-03-31 | −210.42% | −106.86 pp |
| Q4 2022 | 2022-12-31 | −192.49% | +625.03 pp |
| Q3 2022 | 2022-09-30 | −595.21% | −627.90 pp |
| Q2 2022 | 2022-06-30 | −262.44% | +286.87 pp |
| Q1 2022 | 2022-03-31 | −103.56% | +79.70 pp |
| Q4 2021 | 2021-12-31 | −817.52% | −728.29 pp |
| Q3 2021 | 2021-09-30 | 32.68% | −40.74 pp |
| Q2 2021 | 2021-06-30 | −549.31% | −350.80 pp |
| Q1 2021 | 2021-03-31 | −183.27% | +148.99 pp |
| Q4 2020 | 2020-12-31 | −89.23% | +1170.31 pp |
| Q3 2020 | 2020-09-30 | 73.42% | +232.75 pp |
| Q2 2020 | 2020-06-30 | −198.51% | −257.40 pp |
| Q1 2020 | 2020-03-31 | −332.26% | −127.58 pp |
| Q4 2019 | 2019-12-31 | −1,259.54% | −1277.98 pp |
| Q3 2019 | 2019-09-30 | −159.32% | −11.97 pp |
| Q2 2019 | 2019-06-30 | 58.89% | +111.77 pp |
| Q1 2019 | 2019-03-31 | −204.68% | −77.51 pp |
| Q4 2018 | 2018-12-31 | 18.43% | +134.21 pp |
| Q3 2018 | 2018-09-30 | −147.35% | −91.28 pp |
| Q2 2018 | 2018-06-30 | −52.88% | +46.69 pp |
| Q1 2018 | 2018-03-31 | −127.17% | −29.28 pp |
| Q4 2017 | 2017-12-31 | −115.77% | −37.89 pp |
| Q3 2017 | 2017-09-30 | −56.08% | +17.35 pp |
| Q2 2017 | 2017-06-30 | −99.57% | −129.27 pp |
| Q1 2017 | 2017-03-31 | −97.89% | −3.18 pp |
| Q4 2016 | 2016-12-31 | −77.88% | +120.33 pp |
| Q3 2016 | 2016-09-30 | −73.42% | +150.60 pp |
| Q2 2016 | 2016-06-30 | 29.70% | −19.51 pp |
| Q1 2016 | 2016-03-31 | −94.71% | +179.70 pp |
| Q4 2015 | 2015-12-31 | −198.21% | +99.67 pp |
| Q3 2015 | 2015-09-30 | −224.02% | +47.49 pp |
| Q2 2015 | 2015-06-30 | 49.20% | −5.46 pp |
| Q1 2015 | 2015-03-31 | −274.41% | −194.94 pp |
| Q4 2014 | 2014-12-31 | −297.88% | — |
| Q3 2014 | 2014-09-30 | −271.52% | — |
| Q2 2014 | 2014-06-30 | 54.66% | — |
| Q1 2014 | 2014-03-31 | −79.47% | — |
Over the last five reported fiscal years, Kyntra Bio's operating margin decreased from −108.83% to −712.66%, a change of −603.83 percentage points. The latest reported quarter, Q1 2026, shows −369.66%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kyntra Bio filings at SEC.gov ↗